Melanoma News

CancerConnect melanoma news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of melanoma research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of melanoma treatment and survivorship.

Share

Melanoma News


Viagra Associated with Increased Risk of Melanoma (April 18, 2014)

Men who take by Viagra (sildenafil) are 84 percent more likely to develop melanoma than men who do not, according to the results of a study published in JAMA Internal Medicine. Melanoma is a potentially... Continue Reading

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma (March 28, 2014)

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study... Continue Reading

Nivolumab Produces Durable Responses in Advanced Melanoma (March 14, 2014)

Nivolumab, an investigational, anti–PD-1 drug, produced durable responses in patients with advanced melanoma, according to the results of a study published in the Journal of Clinical Oncology. Of the... Continue Reading

FDA Approves Mekinist in Combination with Tafinlar for Advanced Melanoma (January 13, 2014)

The U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) in combination with Tafinlar® (dabrafenib) to treat patients with advanced melanoma. Of the more than one million new diagnoses... Continue Reading

Marriage May Have a Protective Effect for Cancer Patients (December 17, 2013)

Social support may have a significant impact on cancer detection, treatment, and survival, according to the results of a study published in the Journal of Clinical Oncology. The study showed that married... Continue Reading

The Melanoma Research Foundation (December 4, 2013)

One dedicated patient’s dream becomes a reality, as melanoma education, research, and advocacy become the passionate focus for a committed group of survivors, families, and friends. By Diana Price According... Continue Reading

Yervoy Shows Long-Term Survival Advantage in Advanced Melanoma (October 23, 2013)

Patients with advanced melanoma have lived as long as ten years when treated with the immunologic therapy Yervoy® (ipilimumab), according to pooled data presented at the ESMO 2013 Congress of the European... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact,... Continue Reading

Tafinlar Shows Promise in BRAF-600E/K Mutant Metastatic Melanoma (August 28, 2013)

The targeted agent Tafinlar® (dabrafenib) produced a high response rate in patients with metastatic melanoma with a BRAF-V600E mutation, according to the results of a study published in the Journal of... Continue Reading

Melanoma More Deadly in Young White Men than Women (August 12, 2013)

Adolescent and young white men with melanoma are more than 50 percent more likely than their female counterparts to die from the disease, according to the results of a study published in JAMA Dermatology.[1] Melanoma... Continue Reading

More Melanoma News

Latest Melanoma News By Stage


Screening/Prevention

Viagra Associated with Increased Risk of Melanoma (April 18, 2014)

Men who take by Viagra (sildenafil) are 84 percent more likely to develop melanoma than men who do not, according to the results of a study published in JAMA Internal Medicine. Melanoma is a potentially fatal type of skin cancer that begins in the melanocytes,... Continue Reading

Aspirin Reduces Risk of Melanoma in Women (March 20, 2013)

Women who regularly take aspirin have a reduced risk of developing melanoma, according to the results of a study published in Cancer.[1] What’s more—the longer they take the aspirin, the lower the risk. Of the more than one million new diagnoses of... Continue Reading

Lymphoma Patients and Transplant Recipients at Higher Risk of Melanoma (October 11, 2012)

Individuals with lymphoma or those who have undergone organ transplants are far more likely than the average person to develop—and die from—melanoma, according to the results of a review published in Mayo Clinic Proceedings. Melanoma is a potentially... Continue Reading

Number of Cancer Survivors Will Grow to 18 Million by 2022 (June 25, 2012)

There will be nearly 18 million cancer survivors in the United States by 2022, according to a report by the American Cancer Society and the National Cancer Institute: Cancer Treatment & Survivorship Facts & Figures[1] and an accompanying journal... Continue Reading

NSAIDs Might Reduce Risk of Skin Cancer (June 4, 2012)

The use of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen may reduce the risk of developing skin cancer, according to a recent study published in the journal Cancer.[1] Skin cancer is the most commonly diagnosed cancer in... Continue Reading

More Screening and Prevention

Stages I-II

Melanoma More Deadly in Young White Men than Women (August 12, 2013)

Adolescent and young white men with melanoma are more than 50 percent more likely than their female counterparts to die from the disease, according to the results of a study published in JAMA Dermatology.[1] Melanoma is a deadly type of skin cancer that... Continue Reading

Lymphoseek Approved for Detecting Lymph Nodes in Breast Cancer and Melanoma (April 10, 2013)

The U.S. Food and Drug Administration (FDA) has approved Lymphoseek® (technetium Tc 99m tilmanocept) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing... Continue Reading

Adjuvant Radiotherapy for the Management of High-Risk Malignant Melanoma (September 24, 2012)

Adjuvant radiotherapy significantly improved regional lymphatic control for high-risk patients after therapeutic lymphadenectomy for metastatic melanoma, according to the results of a study published in the Lancet Oncology. Of the more than one million... Continue Reading

Women More Likely to Survive Melanoma Than Men (May 16, 2012)

Women are 30 percent more likely to survive melanoma than men, according to the results of a study published in the Journal of Clinical Oncology.[1] Melanoma is a deadly type of skin cancer that arises from melanocytes, which are cells located in the... Continue Reading

Sentinel Node Biopsy Safe and Effective for Melanomas on Head and Neck (August 10, 2011)

Although the head and neck region is complex and delicate, sentinel lymph node biopsy for melanomas of the head or neck appears to be safe and effective. These results were published in Cancer. Skin cancer is the most commonly diagnosed cancer in the... Continue Reading

More Stages I-II

Stage III

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma (March 28, 2014)

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study presented at the 2014 Society of Surgical Oncology... Continue Reading

FDA Approves Mekinist in Combination with Tafinlar for Advanced Melanoma (January 13, 2014)

The U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) in combination with Tafinlar® (dabrafenib) to treat patients with advanced melanoma. Of the more than one million new diagnoses of skin cancer each year, roughly 76,000... Continue Reading

Yervoy Shows Long-Term Survival Advantage in Advanced Melanoma (October 23, 2013)

Patients with advanced melanoma have lived as long as ten years when treated with the immunologic therapy Yervoy® (ipilimumab), according to pooled data presented at the ESMO 2013 Congress of the European Society for Medical Oncology in Amsterdam. Of... Continue Reading

Melanoma More Deadly in Young White Men than Women (August 12, 2013)

Adolescent and young white men with melanoma are more than 50 percent more likely than their female counterparts to die from the disease, according to the results of a study published in JAMA Dermatology.[1] Melanoma is a deadly type of skin cancer that... Continue Reading

Investigational Melanoma Drug Shrinks Tumors in Phase III Trial (July 2, 2013)

In a Phase III clinical trial, the investigational drug T-VEC (talimogene laherparepvec) produced durable responses in people with advanced melanoma.  These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology... Continue Reading

More Stage III

Stage IV

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma (March 28, 2014)

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study presented at the 2014 Society of Surgical Oncology... Continue Reading

Nivolumab Produces Durable Responses in Advanced Melanoma (March 14, 2014)

Nivolumab, an investigational, anti–PD-1 drug, produced durable responses in patients with advanced melanoma, according to the results of a study published in the Journal of Clinical Oncology. Of the more than one million new diagnoses of skin cancer... Continue Reading

FDA Approves Mekinist in Combination with Tafinlar for Advanced Melanoma (January 13, 2014)

The U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) in combination with Tafinlar® (dabrafenib) to treat patients with advanced melanoma. Of the more than one million new diagnoses of skin cancer each year, roughly 76,000... Continue Reading

Yervoy Shows Long-Term Survival Advantage in Advanced Melanoma (October 23, 2013)

Patients with advanced melanoma have lived as long as ten years when treated with the immunologic therapy Yervoy® (ipilimumab), according to pooled data presented at the ESMO 2013 Congress of the European Society for Medical Oncology in Amsterdam. Of... Continue Reading

Tafinlar Shows Promise in BRAF-600E/K Mutant Metastatic Melanoma (August 28, 2013)

The targeted agent Tafinlar® (dabrafenib) produced a high response rate in patients with metastatic melanoma with a BRAF-V600E mutation, according to the results of a study published in the Journal of Clinical Oncology. Of the more than one million new... Continue Reading

More Stage IV

Recurrent

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma (March 28, 2014)

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study presented at the 2014 Society of Surgical Oncology... Continue Reading

Nivolumab Produces Durable Responses in Advanced Melanoma (March 14, 2014)

Nivolumab, an investigational, anti–PD-1 drug, produced durable responses in patients with advanced melanoma, according to the results of a study published in the Journal of Clinical Oncology. Of the more than one million new diagnoses of skin cancer... Continue Reading

FDA Approves Mekinist in Combination with Tafinlar for Advanced Melanoma (January 13, 2014)

The U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) in combination with Tafinlar® (dabrafenib) to treat patients with advanced melanoma. Of the more than one million new diagnoses of skin cancer each year, roughly 76,000... Continue Reading

Yervoy Shows Long-Term Survival Advantage in Advanced Melanoma (October 23, 2013)

Patients with advanced melanoma have lived as long as ten years when treated with the immunologic therapy Yervoy® (ipilimumab), according to pooled data presented at the ESMO 2013 Congress of the European Society for Medical Oncology in Amsterdam. Of... Continue Reading

Tafinlar Shows Promise in BRAF-600E/K Mutant Metastatic Melanoma (August 28, 2013)

The targeted agent Tafinlar® (dabrafenib) produced a high response rate in patients with metastatic melanoma with a BRAF-V600E mutation, according to the results of a study published in the Journal of Clinical Oncology. Of the more than one million new... Continue Reading

More Recurrent

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Just another WordPress weblog
Facebook Twitter RSS